Clinical Trial Update: A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating immune phenotype biomarkers in relapsing multiple sclerosis patients treated with fingolimod 0.5 mg; completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Fingolimod (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2020-07-21